Samsung Biologics has formalized its independent structure as a 'pure CDMO (Contract Development and Manufacturing Organization) company.' On the 17th, the company presented a proposal for a spin-off at an extraordinary general meeting of shareholders held at Songdo Convensia in Incheon, which passed with a 99.9% approval rate. With this resolution, Samsung Biologics will separate the newly established entity 'Samsung Epis Holdings,' responsible for the biosimilar business, and embark on a full-scale business structure reorganization.

The extraordinary general meeting saw a high shareholder participation rate, with 93% of voting shares present. The company stated, "The spin-off proposal was overwhelmingly approved by attending shareholders. The blueprint for sustainable growth has been completed."

This reorganization, conducted through a spin-off, will allocate shares of the surviving company, Samsung Biologics, and the newly established company, Samsung Epis Holdings, to existing shareholders in a ratio of 0.6503913 to 0.3496087, respectively. The spin-off date is set for November 1, with trading suspended from October 30 to November 21, followed by a change and re-listing on the Korea Exchange on November 24.

Through this spin-off, Samsung Biologics plans to focus on its development and production-centered business, strengthening its position as a 'Top-Tier' player in the global CDMO market. Meanwhile, the newly established Samsung Epis Holdings will hold a 100% stake in the biosimilar specialist company Samsung Bioepis and will lead future bio-technology investments and new business ventures.

Industry observers view this spin-off as an opportunity to enhance Samsung Biologics' business transparency and fundamentally resolve concerns about conflicts of interest with client companies. Although Samsung Biologics and Samsung Bioepis have been operated under separate decision-making systems, some global pharmaceutical companies have expressed concerns about potential links with the biosimilar business. The company expects to achieve both securing client trust and strengthening order competitiveness through this spin-off.

John Rim, CEO of Samsung Biologics, stated, "This decision is a strategic turning point to enhance the expertise of each business and maximize shareholder value. CDMO and biosimilars will strengthen their growth engines independently according to the characteristics of their respective markets."

The market views this spin-off as the 'beginning of the second act' for Samsung Biologics. Amid the global trend of the CDMO industry's advancement and specialization, the company is analyzed to have established a long-term growth foundation by increasing service focus and establishing an independent management system. A financial investment industry official remarked, "Samsung Biologics, already the world's largest CDMO company by production capacity, can further strengthen client trust and order capabilities through this structural reorganization."

Popular News